Background: Neutropenia (N) is a common chemotherapy (CT) related adverse event and febrile N (FN) often requires hospitalization, being associated with morbidity and mortality. Primary prophylaxis with G-CSF is a common strategy to avoid the onset of FN. Methods: Retrospectively, we evaluated efficacy and safety of daily injections of L (263 μg) from day 5 to 9 (5 total injections) compared with a single injection of P (6 mg) on day 2 in 55 NMBC pts (median age 55 years) during 6 cycles of FEC100 (group A) or 3 cycles of FEC100 followed by further 3 cycles of D100 (group B). Incidence of N, FN and bone pain (BP) (NRS >7) were evaluated. In group A: 35 pts (median age 54 years) received 6 cycles of FEC100. At every cycle, 17 pts received L, while 18 pts one dose of P. In group B: 20 pts (median age 55.5 years) underwent 3 cycles of FEC100 plus 3 of D100. At every cycle, 12 and 8 pts received L and P, respectively. Results: In overall population incidence of N-G3/G4 was 54.5%. In group A: G3/G4-N was 50% and 58% in P and L arm, respectively. One case of FN occurred in P arm. During first cycle, incidence of G3/G4-N was 33% and 41% in P and L arms, respectively; no G3/G4-N occurred during the last cycle. Incidence of BP was 11% in both arms. CT reduction occurred in 50% and 29% in P and L arm, respectively. In group B: G3/G4-N was 25% in P arm and 83% in L arm. No case of FN occurred in both arms. During first cycle, incidence of G3/G4-N was 0% in P and 50% in L arm; while during last cycle no G3/G4-N occurred in the P arm and 25% in L arm. 37% and 50% of pts experienced BP in P and L arm, respectively. CT dose reductions were necessary in 50% of P arm and 58% of L arm. Conclusions: P showed an higher efficacy than L for preventing G3/G4-N in both groups, also in the first cycle, even if the only FN occurred in a patient who was assuming P. There was a higher frequency of BP for L arm in FEC100-D100. In pts assuming FEC100 incidence of CT dose reduction was higher in P arm, while those assuming FEC100-D100 the incidence was higher in L arm.
Single-center experience with pegfilgrastim (P) and lenograstim (L) in nonmetastatic breast cancer (NMBC) patients (pts) during adjuvant FEC100 or sequential FEC100 plus DOCETAXEL100 (D100) / Papa, Anselmo; Rossi, Luigi; Caruso, Davide; Tomao, Federica; Rinaldi, G; Zaccarelli, E; Giordani, E; Verrico, Monica; Strudel, Martina; Spinelli, GIAN PAOLO; Capalbo, Carlo; Lo Russo, G; Evangelista, S; Ricci, F; PERRONE CONGEDI, Francesca; Bianchi, L; Stati, Valeria; Prete, ALESSANDRA ANNA; Tomao, Silverio. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 32:(2014). (Intervento presentato al convegno 50th Annual Meeting of the American-Society-of-Clinical-Oncology tenutosi a Chicago, IL nel MAY 30-JUN 03, 2014).
Single-center experience with pegfilgrastim (P) and lenograstim (L) in nonmetastatic breast cancer (NMBC) patients (pts) during adjuvant FEC100 or sequential FEC100 plus DOCETAXEL100 (D100)
PAPA, ANSELMO;ROSSI, Luigi;CARUSO, DAVIDE;TOMAO, FEDERICA;Rinaldi, G;VERRICO, MONICA;STRUDEL, MARTINA;SPINELLI, GIAN PAOLO;CAPALBO, CARLO;PERRONE CONGEDI, FRANCESCA;STATI, VALERIA;PRETE, ALESSANDRA ANNA;TOMAO, SILVERIO
2014
Abstract
Background: Neutropenia (N) is a common chemotherapy (CT) related adverse event and febrile N (FN) often requires hospitalization, being associated with morbidity and mortality. Primary prophylaxis with G-CSF is a common strategy to avoid the onset of FN. Methods: Retrospectively, we evaluated efficacy and safety of daily injections of L (263 μg) from day 5 to 9 (5 total injections) compared with a single injection of P (6 mg) on day 2 in 55 NMBC pts (median age 55 years) during 6 cycles of FEC100 (group A) or 3 cycles of FEC100 followed by further 3 cycles of D100 (group B). Incidence of N, FN and bone pain (BP) (NRS >7) were evaluated. In group A: 35 pts (median age 54 years) received 6 cycles of FEC100. At every cycle, 17 pts received L, while 18 pts one dose of P. In group B: 20 pts (median age 55.5 years) underwent 3 cycles of FEC100 plus 3 of D100. At every cycle, 12 and 8 pts received L and P, respectively. Results: In overall population incidence of N-G3/G4 was 54.5%. In group A: G3/G4-N was 50% and 58% in P and L arm, respectively. One case of FN occurred in P arm. During first cycle, incidence of G3/G4-N was 33% and 41% in P and L arms, respectively; no G3/G4-N occurred during the last cycle. Incidence of BP was 11% in both arms. CT reduction occurred in 50% and 29% in P and L arm, respectively. In group B: G3/G4-N was 25% in P arm and 83% in L arm. No case of FN occurred in both arms. During first cycle, incidence of G3/G4-N was 0% in P and 50% in L arm; while during last cycle no G3/G4-N occurred in the P arm and 25% in L arm. 37% and 50% of pts experienced BP in P and L arm, respectively. CT dose reductions were necessary in 50% of P arm and 58% of L arm. Conclusions: P showed an higher efficacy than L for preventing G3/G4-N in both groups, also in the first cycle, even if the only FN occurred in a patient who was assuming P. There was a higher frequency of BP for L arm in FEC100-D100. In pts assuming FEC100 incidence of CT dose reduction was higher in P arm, while those assuming FEC100-D100 the incidence was higher in L arm.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
